Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Canaccord Fireside Chat & pelareorep's approval in mBC

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Aug 12, 2023 9:15pm

157 Views

Post# 35585684

RE:Canaccord Fireside Chat & pelareorep's approval in mBC

Both Matt and Kirk spoke to the prospect of moving pelareorep into Phase 3 trials in both breast and pancreatic cancer. Listen to the archived webcast at the timestamps that I referenced. The Phase 3 in metastatic breast cancer would be with the doublet of pelareorep + paclitaxel, which corresponds to ONCY's IND-213 and BRACELET-1 response findings.

Furthermore the US$ 10 Billion acquisition value is still in scope, unlike what others are trying to suggest.

<< Previous

Bullboard Posts

Next >>

Quebecor achieves all Freedom Mobile acquisition commitments